Ultragenyx Germany - Pharma in Berlin

Ultragenyx Germany GmbH Adresse & Kontakt

Telefon

Website

Email

Adresse

Rahel-Hirsch-Str. 10
10557 Berlin

Häufige Fragen zu Ultragenyx Germany GmbH

Was macht Ultragenyx Germany GmbH?

Das Arbeitsgebiet von Ultragenyx Germany GmbH ist das Erforschen seltener, erblich bedingter Krankheiten. Dazu gehören z.B. Morbus Sly, Morbus Cori und Morbus Wilson. Ultragenyx entwickelt verschiedene Therapien mit unterschiedlichen Medikamenten. Zum Einsatz kommen traditionelle Biologika, Gentherapien oder Nukleinsäuretherapien. Außerdem hat Ultragenyx das Entwicklungsverfahren für Medikamente beschleunigt.

Ultragenyx Germany GmbH: A Leading Force in Rare Disease Treatment

Ultragenyx Germany GmbH, based in Frankfurt am Main, is a subsidiary of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company committed to bringing novel products to patients with rare diseases. The company's operations span various areas of the pharmaceutical industry, including the research, development, and commercialization of innovative drugs for the treatment of rare and ultra-rare genetic diseases.

History of Ultragenyx Pharmaceutical Inc.

The parent company, Ultragenyx Pharmaceutical Inc., was founded in 2010 by Emil D. Kakkis, a physician and scientist who has dedicated his career to developing medicines for rare diseases. Headquartered in Novato, California, Ultragenyx has a global presence with additional locations in Europe, Latin America, and Asia.

Focus on Rare Genetic Diseases

The primary focus of Ultragenyx Germany GmbH is on diseases that affect a small number of patients worldwide. These are often genetic disorders that are present from birth and can have a significant impact on lifespan and quality of life. The company's mission is to make a meaningful difference in the lives of patients suffering from these rare genetic diseases through the development of novel treatments.

Product Portfolio

Ultragenyx Germany GmbH's product portfolio is diverse, aiming to cover a range of rare and ultra-rare diseases. Some of the company's most notable products include Crysvita, Mepsevii, and Dojolvi. These drugs are used to treat conditions such as X-linked hypophosphatemia, mucopolysaccharidosis VII, and long-chain fatty acid oxidation disorders, respectively.

Research and Development

Ultragenyx Germany GmbH is heavily invested in research and development. The company is continually working on new drug candidates and treatment methods, often in collaboration with other leading pharmaceutical and biotechnology companies. This commitment to innovation has resulted in a robust pipeline of potential treatments for various rare genetic diseases.

Commitment to Patients

One of the core values of Ultragenyx Germany GmbH is its unwavering commitment to patients. The company goes beyond just developing treatments; it also provides comprehensive support services for patients and their families. These services include disease education, assistance with access to medications, and various patient advocacy initiatives.

Future of Ultragenyx Germany GmbH

Looking ahead, Ultragenyx Germany GmbH is poised to continue its growth and innovation in the field of rare disease treatment. With a strong pipeline of potential new treatments and a relentless commitment to patient care, the company is well-positioned to make significant strides in improving the lives of patients with rare genetic diseases.

Ultragenyx Germany GmbH is truly a leading force in the field of rare disease treatment, embodying the spirit of innovation, dedication, and compassion that is required to make a meaningful difference in the lives of patients with rare genetic diseases.